SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : MGI Pharma MOGN New patents, anti cancer
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (215)9/20/1997 6:45:00 AM
From: David Cathcart   of 1826
 
To everyone:

I spoke to Lori Weiman yesterday and she said the following:

** The issue of the second phase I trial for MGI 114 is absolutely nothing more than to increase the number of patients exposed to the drug. The dose regimen change is a minor issue. To me, the "trusting" one, this makes perfect sense. More patients = more signs of efficacy (hopefully) = more useful data entering phase II. This would tie in with Richard Dean Bagnell's theory of the involvement of the NCI expanding the potential of MGI 114 in phase II.

** They started at such a low dose rate in the first phase I trial because canines were relatively sensitive to the drug (JVM posted something to this effect earlier). Before human clinical trials, there is no way to know if humans are more like dogs or mice (if either), so the doctors must be conservative when dealing with a human life. It is important to note that humans may not be like either dogs or mice. So, though we are approaching the level where mice showed 100% efficacy in some tests, the same may not hold true for humans. To me, the one who is optimistic as well as trusting, after seeing three cases of efficacy at lower dose rates I think we are going to soon see great results.

** They will release the quarterly figures the week of October 13th and it will likely be before the opening on October 15th. I for one am anxiously and optimistically anticipating those figures.

** Management at MGI follows this thread on SI.

I wrote to Lori in a separate e-mail asking her if MGI would consider posting minor news updates on SI as does the management of Alfacell (ACEL) on that thread. For example, the esoteric milestone events from the MGI 114 trials - does level changes, signs of efficacy, etc. -- would be overkill to make a formal news release but appropriate for the avid investors (rabid lunatics?) at SI. The releases could be short and informal and have the added benefit of curbing some of the speculation.

David
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News